Interferon-Associated Antigen Binding Proteins for HBV Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating hepatitis B virus (HBV) infection are inadequate in effectively disrupting viral replication and reducing HBV viral load in infected cells.
Innovation Solution
Development of interferon-associated antigen binding proteins comprising an agonistic anti-CD40 antibody or its antigen binding fragment, combined with Interferon (IFN) or its functional fragment, which specifically target and inhibit HBV replication by reducing the transcription of covalently closed circular HBV DNA and pre-genomic HBV RNA in infected cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatment methods are used for HBV infection, then treatment is provided, but viral replication is not effectively disrupted and HBV viral load is not reduced
Solution Approach 1:
The patent combines an agonistic anti-CD40 antibody with interferon (IFN) or a functional fragment thereof into a single interferon-associated antigen binding protein. This merging of two therapeutic components (anti-CD40 antibody and IFN) into one molecule allows simultaneous activation of CD40 receptors and IFN pathways, thereby effectively disrupting HBV replication and reducing viral load where current single-modality treatments have failed
Solution Approach 2:
The invention creates a composite therapeutic protein structure consisting of an agonistic anti-CD40 antibody portion and an interferon portion. This composite structure integrates the immunomodulatory effects of CD40 agonism with the antiviral effects of interferon, providing enhanced reliability in disrupting viral replication compared to conventional monotherapy approaches
Data Source
AI summary
The present invention relates to novel interferon-associated antigen binding proteins as well as nucleic acids, vectors and vector systems encoding such interferon-associated antigen binding proteins. The present invention also relates to compositions comprising such interferon-associated antigen binding proteins, nucleic acids, vectors and vector systems. The novel interferon-associated antigen binding proteins afford beneficial improvements over the current state of the art, for example inthat they effectively disrupt viral replication and thereby reduce HBV viral load. Thus, the present invention also provides medical uses of such interferon-associated antigen binding proteins, nucleic acids, vectors, vector systems and compositions, e.g., in the treatment of hepatitis B virus (HBV) infection and/or for decreasing one or more symptoms of HBV infection in a subject. The present invention further provides host cells comprising such nucleic acids, vectors and vector systems as well as methods of making the interferon-associated antigen binding proteins according to the invention using said host cells.